Samuel Denmeade, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Johns Hopkins University School Of Medicine - Baltimore MD
Rank: Full Professor
Years: 1998-Present

Johns Hopkins Hospital
Rank: Full Professor
Years: 1998-Present

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
J Clinical Investigatiou
Volume: 132
Date: 12 2022

Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer
European J Cancer
Volume: 181
Date: 03 2023

Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer
Oncologist
Volume: 28
Date: 06 2023

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Natue Communications
Volume: 15
Date: 01 2024

Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer
J Clin Oncol
Volume: 42
Date: 03 2024